CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc. CBAY Peers
See (CBAY) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CBAY | $32.48 | +0.03% | 3.73B | -32.81 | -$0.99 | N/A |
| VRTX | $438.65 | +0.98% | 112.64B | -114.83 | -$3.82 | N/A |
| REGN | $594.32 | +1.59% | 63.09B | 15.10 | $39.37 | +0.15% |
| SGEN | $228.74 | -0.07% | 43.15B | -57.19 | -$4.00 | N/A |
| ALNY | $285.31 | +0.67% | 37.20B | -135.86 | -$2.10 | N/A |
| ARGX | $565.63 | +0.69% | 34.54B | 34.47 | $16.41 | N/A |
| BNTX | $92.77 | +0.47% | 22.30B | -26.06 | -$3.56 | N/A |
| BGNE | $184.71 | +0.49% | 20.21B | -22.55 | -$8.19 | N/A |
| RPRX | $34.02 | +2.72% | 19.13B | 13.89 | $2.45 | +2.53% |
| DNA-WT | $0.27 | -2.76% | 18.73B | N/A | N/A | N/A |
Stock Comparison
CBAY vs VRTX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, VRTX has a market cap of 112.64B. Regarding current trading prices, CBAY is priced at $32.48, while VRTX trades at $438.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas VRTX's P/E ratio is -114.83. In terms of profitability, CBAY's ROE is -0.32%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, CBAY is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs REGN Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, REGN has a market cap of 63.09B. Regarding current trading prices, CBAY is priced at $32.48, while REGN trades at $594.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas REGN's P/E ratio is 15.10. In terms of profitability, CBAY's ROE is -0.32%, compared to REGN's ROE of +0.15%. Regarding short-term risk, CBAY is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs SGEN Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, SGEN has a market cap of 43.15B. Regarding current trading prices, CBAY is priced at $32.48, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CBAY's ROE is -0.32%, compared to SGEN's ROE of -0.17%. Regarding short-term risk, CBAY is less volatile compared to SGEN. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs ALNY Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, ALNY has a market cap of 37.20B. Regarding current trading prices, CBAY is priced at $32.48, while ALNY trades at $285.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ALNY's P/E ratio is -135.86. In terms of profitability, CBAY's ROE is -0.32%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, CBAY is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs ARGX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, ARGX has a market cap of 34.54B. Regarding current trading prices, CBAY is priced at $32.48, while ARGX trades at $565.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ARGX's P/E ratio is 34.47. In terms of profitability, CBAY's ROE is -0.32%, compared to ARGX's ROE of +0.16%. Regarding short-term risk, CBAY is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs BNTX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, BNTX has a market cap of 22.30B. Regarding current trading prices, CBAY is priced at $32.48, while BNTX trades at $92.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas BNTX's P/E ratio is -26.06. In terms of profitability, CBAY's ROE is -0.32%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, CBAY is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs BGNE Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, BGNE has a market cap of 20.21B. Regarding current trading prices, CBAY is priced at $32.48, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CBAY's ROE is -0.32%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, CBAY is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs RPRX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, RPRX has a market cap of 19.13B. Regarding current trading prices, CBAY is priced at $32.48, while RPRX trades at $34.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas RPRX's P/E ratio is 13.89. In terms of profitability, CBAY's ROE is -0.32%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, CBAY is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs DNA-WT Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, DNA-WT has a market cap of 18.73B. Regarding current trading prices, CBAY is priced at $32.48, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CBAY's ROE is -0.32%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, CBAY is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs SMMT Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, SMMT has a market cap of 16.78B. Regarding current trading prices, CBAY is priced at $32.48, while SMMT trades at $22.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas SMMT's P/E ratio is -66.91. In terms of profitability, CBAY's ROE is -0.32%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, CBAY is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs UTHR Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, UTHR has a market cap of 13.77B. Regarding current trading prices, CBAY is priced at $32.48, while UTHR trades at $305.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas UTHR's P/E ratio is 12.17. In terms of profitability, CBAY's ROE is -0.32%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CBAY is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs KRTX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, KRTX has a market cap of 12.60B. Regarding current trading prices, CBAY is priced at $32.48, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CBAY's ROE is -0.32%, compared to KRTX's ROE of -0.25%. Regarding short-term risk, CBAY is less volatile compared to KRTX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs EXEL Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, EXEL has a market cap of 12.38B. Regarding current trading prices, CBAY is priced at $32.48, while EXEL trades at $45.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas EXEL's P/E ratio is 25.80. In terms of profitability, CBAY's ROE is -0.32%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, CBAY is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs GMAB Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, GMAB has a market cap of 12.33B. Regarding current trading prices, CBAY is priced at $32.48, while GMAB trades at $19.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas GMAB's P/E ratio is 11.69. In terms of profitability, CBAY's ROE is -0.32%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, CBAY is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs INCY Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, INCY has a market cap of 12.25B. Regarding current trading prices, CBAY is priced at $32.48, while INCY trades at $63.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas INCY's P/E ratio is 316.55. In terms of profitability, CBAY's ROE is -0.32%, compared to INCY's ROE of +0.01%. Regarding short-term risk, CBAY is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs BMRN Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, BMRN has a market cap of 11.37B. Regarding current trading prices, CBAY is priced at $32.48, while BMRN trades at $59.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas BMRN's P/E ratio is 21.95. In terms of profitability, CBAY's ROE is -0.32%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, CBAY is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs MRNA Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, MRNA has a market cap of 9.61B. Regarding current trading prices, CBAY is priced at $32.48, while MRNA trades at $24.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas MRNA's P/E ratio is -2.85. In terms of profitability, CBAY's ROE is -0.32%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, CBAY is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs RXDX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, RXDX has a market cap of 9.56B. Regarding current trading prices, CBAY is priced at $32.48, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CBAY's ROE is -0.32%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CBAY is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for CBAY.
CBAY vs ASND Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, ASND has a market cap of 9.51B. Regarding current trading prices, CBAY is priced at $32.48, while ASND trades at $157.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ASND's P/E ratio is -24.28. In terms of profitability, CBAY's ROE is -0.32%, compared to ASND's ROE of +1.91%. Regarding short-term risk, CBAY is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs IMGN Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, IMGN has a market cap of 8.73B. Regarding current trading prices, CBAY is priced at $32.48, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CBAY's ROE is -0.32%, compared to IMGN's ROE of +0.05%. Regarding short-term risk, CBAY is less volatile compared to IMGN. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs CERE Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, CERE has a market cap of 8.19B. Regarding current trading prices, CBAY is priced at $32.48, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas CERE's P/E ratio is -16.47. In terms of profitability, CBAY's ROE is -0.32%, compared to CERE's ROE of -0.99%. Regarding short-term risk, CBAY is less volatile compared to CERE. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs CORT Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, CORT has a market cap of 7.96B. Regarding current trading prices, CBAY is priced at $32.48, while CORT trades at $75.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas CORT's P/E ratio is 65.29. In terms of profitability, CBAY's ROE is -0.32%, compared to CORT's ROE of +0.20%. Regarding short-term risk, CBAY is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs ROIVW Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, ROIVW has a market cap of 7.83B. Regarding current trading prices, CBAY is priced at $32.48, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, CBAY's ROE is -0.32%, compared to ROIVW's ROE of -0.02%. Regarding short-term risk, CBAY is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs TECH Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, TECH has a market cap of 7.71B. Regarding current trading prices, CBAY is priced at $32.48, while TECH trades at $49.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas TECH's P/E ratio is 59.22. In terms of profitability, CBAY's ROE is -0.32%, compared to TECH's ROE of +0.06%. Regarding short-term risk, CBAY is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs ROIV Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, ROIV has a market cap of 7.70B. Regarding current trading prices, CBAY is priced at $32.48, while ROIV trades at $10.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ROIV's P/E ratio is -10.79. In terms of profitability, CBAY's ROE is -0.32%, compared to ROIV's ROE of -0.02%. Regarding short-term risk, CBAY is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs RVMD Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, RVMD has a market cap of 7.37B. Regarding current trading prices, CBAY is priced at $32.48, while RVMD trades at $39.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas RVMD's P/E ratio is -9.86. In terms of profitability, CBAY's ROE is -0.32%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, CBAY is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs JAZZ Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, JAZZ has a market cap of 6.72B. Regarding current trading prices, CBAY is priced at $32.48, while JAZZ trades at $108.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas JAZZ's P/E ratio is 14.81. In terms of profitability, CBAY's ROE is -0.32%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, CBAY is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs BPMC Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, BPMC has a market cap of 6.57B. Regarding current trading prices, CBAY is priced at $32.48, while BPMC trades at $101.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas BPMC's P/E ratio is -40.51. In terms of profitability, CBAY's ROE is -0.32%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, CBAY is less volatile compared to BPMC. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs RETA Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, RETA has a market cap of 6.57B. Regarding current trading prices, CBAY is priced at $32.48, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas RETA's P/E ratio is -66.29. In terms of profitability, CBAY's ROE is -0.32%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CBAY is less volatile compared to RETA. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs MDGL Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, MDGL has a market cap of 6.46B. Regarding current trading prices, CBAY is priced at $32.48, while MDGL trades at $290.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas MDGL's P/E ratio is -16.32. In terms of profitability, CBAY's ROE is -0.32%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, CBAY is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs BBIO Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, BBIO has a market cap of 6.43B. Regarding current trading prices, CBAY is priced at $32.48, while BBIO trades at $33.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas BBIO's P/E ratio is -9.51. In terms of profitability, CBAY's ROE is -0.32%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, CBAY is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs HALO Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, HALO has a market cap of 6.41B. Regarding current trading prices, CBAY is priced at $32.48, while HALO trades at $52.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas HALO's P/E ratio is 13.84. In terms of profitability, CBAY's ROE is -0.32%, compared to HALO's ROE of +1.22%. Regarding short-term risk, CBAY is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs VRNA Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, VRNA has a market cap of 6.06B. Regarding current trading prices, CBAY is priced at $32.48, while VRNA trades at $71.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas VRNA's P/E ratio is -35.65. In terms of profitability, CBAY's ROE is -0.32%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, CBAY is less volatile compared to VRNA. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs TLX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, TLX has a market cap of 5.58B. Regarding current trading prices, CBAY is priced at $32.48, while TLX trades at $16.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas TLX's P/E ratio is 185.38. In terms of profitability, CBAY's ROE is -0.32%, compared to TLX's ROE of +0.14%. Regarding short-term risk, CBAY is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs ABCM Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, ABCM has a market cap of 5.52B. Regarding current trading prices, CBAY is priced at $32.48, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CBAY's ROE is -0.32%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CBAY is less volatile compared to ABCM. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs ISEE Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, ISEE has a market cap of 5.51B. Regarding current trading prices, CBAY is priced at $32.48, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CBAY's ROE is -0.32%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CBAY is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs TGTX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, TGTX has a market cap of 5.45B. Regarding current trading prices, CBAY is priced at $32.48, while TGTX trades at $34.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas TGTX's P/E ratio is 137.44. In terms of profitability, CBAY's ROE is -0.32%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, CBAY is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs IONS Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, IONS has a market cap of 5.34B. Regarding current trading prices, CBAY is priced at $32.48, while IONS trades at $33.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas IONS's P/E ratio is -11.22. In terms of profitability, CBAY's ROE is -0.32%, compared to IONS's ROE of -0.00%. Regarding short-term risk, CBAY is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs AXSM Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, AXSM has a market cap of 5.29B. Regarding current trading prices, CBAY is priced at $32.48, while AXSM trades at $107.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas AXSM's P/E ratio is -18.64. In terms of profitability, CBAY's ROE is -0.32%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, CBAY is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs NUVL Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, NUVL has a market cap of 5.27B. Regarding current trading prices, CBAY is priced at $32.48, while NUVL trades at $73.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas NUVL's P/E ratio is -16.59. In terms of profitability, CBAY's ROE is -0.32%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, CBAY is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs ALKS Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, ALKS has a market cap of 5.18B. Regarding current trading prices, CBAY is priced at $32.48, while ALKS trades at $31.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ALKS's P/E ratio is 14.28. In terms of profitability, CBAY's ROE is -0.32%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, CBAY is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs ADMA Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, ADMA has a market cap of 4.70B. Regarding current trading prices, CBAY is priced at $32.48, while ADMA trades at $19.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ADMA's P/E ratio is 23.44. In terms of profitability, CBAY's ROE is -0.32%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, CBAY is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs ALPN Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, ALPN has a market cap of 4.46B. Regarding current trading prices, CBAY is priced at $32.48, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CBAY's ROE is -0.32%, compared to ALPN's ROE of -0.15%. Regarding short-term risk, CBAY is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for CBAY.
CBAY vs OPT Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, OPT has a market cap of 4.20B. Regarding current trading prices, CBAY is priced at $32.48, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas OPT's P/E ratio is -1.52. In terms of profitability, CBAY's ROE is -0.32%, compared to OPT's ROE of +2.60%. Regarding short-term risk, CBAY is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for CBAY.
CBAY vs MRTX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, MRTX has a market cap of 4.12B. Regarding current trading prices, CBAY is priced at $32.48, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CBAY's ROE is -0.32%, compared to MRTX's ROE of -0.40%. Regarding short-term risk, CBAY is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs PCVX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, PCVX has a market cap of 4.11B. Regarding current trading prices, CBAY is priced at $32.48, while PCVX trades at $31.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas PCVX's P/E ratio is -7.98. In terms of profitability, CBAY's ROE is -0.32%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, CBAY is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs RYTM Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, RYTM has a market cap of 3.81B. Regarding current trading prices, CBAY is priced at $32.48, while RYTM trades at $59.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas RYTM's P/E ratio is -21.40. In terms of profitability, CBAY's ROE is -0.32%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, CBAY is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs KRYS Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, KRYS has a market cap of 3.77B. Regarding current trading prices, CBAY is priced at $32.48, while KRYS trades at $130.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas KRYS's P/E ratio is 31.32. In terms of profitability, CBAY's ROE is -0.32%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, CBAY is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs RYZB Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, RYZB has a market cap of 3.75B. Regarding current trading prices, CBAY is priced at $32.48, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CBAY's ROE is -0.32%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CBAY is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for CBAY.
CBAY vs ACAD Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, ACAD has a market cap of 3.73B. Regarding current trading prices, CBAY is priced at $32.48, while ACAD trades at $22.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ACAD's P/E ratio is 16.25. In terms of profitability, CBAY's ROE is -0.32%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, CBAY is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs CYTK Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, CYTK has a market cap of 3.70B. Regarding current trading prices, CBAY is priced at $32.48, while CYTK trades at $31.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas CYTK's P/E ratio is -5.86. In terms of profitability, CBAY's ROE is -0.32%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, CBAY is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs RNA Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, RNA has a market cap of 3.66B. Regarding current trading prices, CBAY is priced at $32.48, while RNA trades at $30.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas RNA's P/E ratio is -10.12. In terms of profitability, CBAY's ROE is -0.32%, compared to RNA's ROE of -0.27%. Regarding short-term risk, CBAY is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs PTCT Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, PTCT has a market cap of 3.65B. Regarding current trading prices, CBAY is priced at $32.48, while PTCT trades at $46.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas PTCT's P/E ratio is 7.07. In terms of profitability, CBAY's ROE is -0.32%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, CBAY is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs SRPT Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, SRPT has a market cap of 3.58B. Regarding current trading prices, CBAY is priced at $32.48, while SRPT trades at $36.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas SRPT's P/E ratio is -13.80. In terms of profitability, CBAY's ROE is -0.32%, compared to SRPT's ROE of -0.20%. Regarding short-term risk, CBAY is less volatile compared to SRPT. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs SWTX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, SWTX has a market cap of 3.47B. Regarding current trading prices, CBAY is priced at $32.48, while SWTX trades at $46.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas SWTX's P/E ratio is -13.52. In terms of profitability, CBAY's ROE is -0.32%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, CBAY is less volatile compared to SWTX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs RARE Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, RARE has a market cap of 3.37B. Regarding current trading prices, CBAY is priced at $32.48, while RARE trades at $35.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas RARE's P/E ratio is -6.11. In terms of profitability, CBAY's ROE is -0.32%, compared to RARE's ROE of -1.86%. Regarding short-term risk, CBAY is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs CRSP Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, CRSP has a market cap of 3.35B. Regarding current trading prices, CBAY is priced at $32.48, while CRSP trades at $38.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas CRSP's P/E ratio is -8.63. In terms of profitability, CBAY's ROE is -0.32%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, CBAY is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs ACLX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, ACLX has a market cap of 3.24B. Regarding current trading prices, CBAY is priced at $32.48, while ACLX trades at $58.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ACLX's P/E ratio is -19.66. In terms of profitability, CBAY's ROE is -0.32%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, CBAY is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs SLNO Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, SLNO has a market cap of 3.21B. Regarding current trading prices, CBAY is priced at $32.48, while SLNO trades at $69.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas SLNO's P/E ratio is -15.97. In terms of profitability, CBAY's ROE is -0.32%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, CBAY is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs VKTX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, VKTX has a market cap of 3.19B. Regarding current trading prices, CBAY is priced at $32.48, while VKTX trades at $28.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas VKTX's P/E ratio is -24.51. In terms of profitability, CBAY's ROE is -0.32%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, CBAY is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs MTSR Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, MTSR has a market cap of 3.10B. Regarding current trading prices, CBAY is priced at $32.48, while MTSR trades at $29.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas MTSR's P/E ratio is -11.67. In terms of profitability, CBAY's ROE is -0.32%, compared to MTSR's ROE of -0.55%. Regarding short-term risk, CBAY is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs AKRO Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, AKRO has a market cap of 3.10B. Regarding current trading prices, CBAY is priced at $32.48, while AKRO trades at $38.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas AKRO's P/E ratio is -9.82. In terms of profitability, CBAY's ROE is -0.32%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, CBAY is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs CPRX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, CPRX has a market cap of 2.97B. Regarding current trading prices, CBAY is priced at $32.48, while CPRX trades at $24.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas CPRX's P/E ratio is 15.52. In terms of profitability, CBAY's ROE is -0.32%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, CBAY is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs CRNX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, CRNX has a market cap of 2.93B. Regarding current trading prices, CBAY is priced at $32.48, while CRNX trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas CRNX's P/E ratio is -8.47. In terms of profitability, CBAY's ROE is -0.32%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, CBAY is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs SRRK Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, SRRK has a market cap of 2.90B. Regarding current trading prices, CBAY is priced at $32.48, while SRRK trades at $30.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas SRRK's P/E ratio is -11.98. In terms of profitability, CBAY's ROE is -0.32%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, CBAY is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs MRUS Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, MRUS has a market cap of 2.88B. Regarding current trading prices, CBAY is priced at $32.48, while MRUS trades at $41.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas MRUS's P/E ratio is -9.99. In terms of profitability, CBAY's ROE is -0.32%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, CBAY is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs MORF Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, MORF has a market cap of 2.86B. Regarding current trading prices, CBAY is priced at $32.48, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas MORF's P/E ratio is -14.88. In terms of profitability, CBAY's ROE is -0.32%, compared to MORF's ROE of -0.27%. Regarding short-term risk, CBAY is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for CBAY.
CBAY vs MOR Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, MOR has a market cap of 2.86B. Regarding current trading prices, CBAY is priced at $32.48, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas MOR's P/E ratio is -12.64. In terms of profitability, CBAY's ROE is -0.32%, compared to MOR's ROE of +7.43%. Regarding short-term risk, CBAY is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs PTGX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, PTGX has a market cap of 2.76B. Regarding current trading prices, CBAY is priced at $32.48, while PTGX trades at $44.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas PTGX's P/E ratio is 57.04. In terms of profitability, CBAY's ROE is -0.32%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, CBAY is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs KDNY Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, KDNY has a market cap of 2.71B. Regarding current trading prices, CBAY is priced at $32.48, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas KDNY's P/E ratio is -12.47. In terms of profitability, CBAY's ROE is -0.32%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, CBAY is less volatile compared to KDNY. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs MYOV Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, MYOV has a market cap of 2.62B. Regarding current trading prices, CBAY is priced at $32.48, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas MYOV's P/E ratio is -14.05. In terms of profitability, CBAY's ROE is -0.32%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, CBAY is less volatile compared to MYOV. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs LEGN Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, LEGN has a market cap of 2.56B. Regarding current trading prices, CBAY is priced at $32.48, while LEGN trades at $27.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas LEGN's P/E ratio is -23.74. In terms of profitability, CBAY's ROE is -0.32%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, CBAY is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs IBRX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, IBRX has a market cap of 2.51B. Regarding current trading prices, CBAY is priced at $32.48, while IBRX trades at $2.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas IBRX's P/E ratio is -4.66. In terms of profitability, CBAY's ROE is -0.32%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, CBAY is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs IMVT Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, IMVT has a market cap of 2.46B. Regarding current trading prices, CBAY is priced at $32.48, while IMVT trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas IMVT's P/E ratio is -5.52. In terms of profitability, CBAY's ROE is -0.32%, compared to IMVT's ROE of -0.78%. Regarding short-term risk, CBAY is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs APGE Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, APGE has a market cap of 2.42B. Regarding current trading prices, CBAY is priced at $32.48, while APGE trades at $40.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas APGE's P/E ratio is -11.25. In terms of profitability, CBAY's ROE is -0.32%, compared to APGE's ROE of -0.19%. Regarding short-term risk, CBAY is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs MLTX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, MLTX has a market cap of 2.39B. Regarding current trading prices, CBAY is priced at $32.48, while MLTX trades at $37.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas MLTX's P/E ratio is -16.36. In terms of profitability, CBAY's ROE is -0.32%, compared to MLTX's ROE of -0.00%. Regarding short-term risk, CBAY is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs PRVB Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, PRVB has a market cap of 2.38B. Regarding current trading prices, CBAY is priced at $32.48, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas PRVB's P/E ratio is -16.43. In terms of profitability, CBAY's ROE is -0.32%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, CBAY is less volatile compared to PRVB. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs LBPH Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, LBPH has a market cap of 2.34B. Regarding current trading prices, CBAY is priced at $32.48, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas LBPH's P/E ratio is -26.66. In terms of profitability, CBAY's ROE is -0.32%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, CBAY is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for CBAY.
CBAY vs XENE Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, XENE has a market cap of 2.32B. Regarding current trading prices, CBAY is priced at $32.48, while XENE trades at $30.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas XENE's P/E ratio is -10.06. In terms of profitability, CBAY's ROE is -0.32%, compared to XENE's ROE of -0.32%. Regarding short-term risk, CBAY is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs VCYT Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, VCYT has a market cap of 2.29B. Regarding current trading prices, CBAY is priced at $32.48, while VCYT trades at $29.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas VCYT's P/E ratio is 94.15. In terms of profitability, CBAY's ROE is -0.32%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, CBAY is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs DICE Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, DICE has a market cap of 2.27B. Regarding current trading prices, CBAY is priced at $32.48, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas DICE's P/E ratio is -21.91. In terms of profitability, CBAY's ROE is -0.32%, compared to DICE's ROE of +0.56%. Regarding short-term risk, CBAY is less volatile compared to DICE. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs MIRM Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, MIRM has a market cap of 2.23B. Regarding current trading prices, CBAY is priced at $32.48, while MIRM trades at $45.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas MIRM's P/E ratio is -27.96. In terms of profitability, CBAY's ROE is -0.32%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, CBAY is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs APLS Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, APLS has a market cap of 2.19B. Regarding current trading prices, CBAY is priced at $32.48, while APLS trades at $17.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas APLS's P/E ratio is -9.69. In terms of profitability, CBAY's ROE is -0.32%, compared to APLS's ROE of -1.00%. Regarding short-term risk, CBAY is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs ARWR Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, ARWR has a market cap of 2.17B. Regarding current trading prices, CBAY is priced at $32.48, while ARWR trades at $15.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas ARWR's P/E ratio is -12.67. In terms of profitability, CBAY's ROE is -0.32%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, CBAY is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs CALT Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, CALT has a market cap of 2.15B. Regarding current trading prices, CBAY is priced at $32.48, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas CALT's P/E ratio is -22.73. In terms of profitability, CBAY's ROE is -0.32%, compared to CALT's ROE of -2.10%. Regarding short-term risk, CBAY is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs BCRX Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, BCRX has a market cap of 2.14B. Regarding current trading prices, CBAY is priced at $32.48, while BCRX trades at $10.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas BCRX's P/E ratio is -39.38. In terms of profitability, CBAY's ROE is -0.32%, compared to BCRX's ROE of +0.15%. Regarding short-term risk, CBAY is less volatile compared to BCRX. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs VCEL Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, VCEL has a market cap of 2.14B. Regarding current trading prices, CBAY is priced at $32.48, while VCEL trades at $42.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas VCEL's P/E ratio is 849.60. In terms of profitability, CBAY's ROE is -0.32%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, CBAY is less volatile compared to VCEL. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs NAMS Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, NAMS has a market cap of 2.12B. Regarding current trading prices, CBAY is priced at $32.48, while NAMS trades at $18.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas NAMS's P/E ratio is -10.26. In terms of profitability, CBAY's ROE is -0.32%, compared to NAMS's ROE of -0.26%. Regarding short-term risk, CBAY is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs BLTE Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, BLTE has a market cap of 2.08B. Regarding current trading prices, CBAY is priced at $32.48, while BLTE trades at $64.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas BLTE's P/E ratio is -54.58. In terms of profitability, CBAY's ROE is -0.32%, compared to BLTE's ROE of -0.31%. Regarding short-term risk, CBAY is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs AAPG Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, AAPG has a market cap of 2.05B. Regarding current trading prices, CBAY is priced at $32.48, while AAPG trades at $23.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas AAPG's P/E ratio is -31.86. In terms of profitability, CBAY's ROE is -0.32%, compared to AAPG's ROE of N/A. Regarding short-term risk, CBAY is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs LGND Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, LGND has a market cap of 2.02B. Regarding current trading prices, CBAY is priced at $32.48, while LGND trades at $104.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas LGND's P/E ratio is -14.36. In terms of profitability, CBAY's ROE is -0.32%, compared to LGND's ROE of -0.16%. Regarding short-term risk, CBAY is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs HRMY Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, HRMY has a market cap of 2.01B. Regarding current trading prices, CBAY is priced at $32.48, while HRMY trades at $35.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas HRMY's P/E ratio is 13.39. In terms of profitability, CBAY's ROE is -0.32%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, CBAY is less volatile compared to HRMY. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs DNLI Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, DNLI has a market cap of 2.00B. Regarding current trading prices, CBAY is priced at $32.48, while DNLI trades at $13.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas DNLI's P/E ratio is -5.16. In terms of profitability, CBAY's ROE is -0.32%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, CBAY is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs FOLD Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, FOLD has a market cap of 1.98B. Regarding current trading prices, CBAY is priced at $32.48, while FOLD trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas FOLD's P/E ratio is -71.44. In terms of profitability, CBAY's ROE is -0.32%, compared to FOLD's ROE of -0.17%. Regarding short-term risk, CBAY is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs KYMR Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, KYMR has a market cap of 1.97B. Regarding current trading prices, CBAY is priced at $32.48, while KYMR trades at $30.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas KYMR's P/E ratio is -9.73. In terms of profitability, CBAY's ROE is -0.32%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, CBAY is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs NAMSW Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, NAMSW has a market cap of 1.94B. Regarding current trading prices, CBAY is priced at $32.48, while NAMSW trades at $8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas NAMSW's P/E ratio is N/A. In terms of profitability, CBAY's ROE is -0.32%, compared to NAMSW's ROE of -0.26%. Regarding short-term risk, CBAY is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs CGON Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, CGON has a market cap of 1.94B. Regarding current trading prices, CBAY is priced at $32.48, while CGON trades at $25.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas CGON's P/E ratio is -16.95. In terms of profitability, CBAY's ROE is -0.32%, compared to CGON's ROE of -0.11%. Regarding short-term risk, CBAY is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs KNSA Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, KNSA has a market cap of 1.92B. Regarding current trading prices, CBAY is priced at $32.48, while KNSA trades at $26.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas KNSA's P/E ratio is -43.75. In terms of profitability, CBAY's ROE is -0.32%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, CBAY is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.
CBAY vs BLU Comparison
CBAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CBAY stands at 3.73B. In comparison, BLU has a market cap of 1.87B. Regarding current trading prices, CBAY is priced at $32.48, while BLU trades at $14.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CBAY currently has a P/E ratio of -32.81, whereas BLU's P/E ratio is -20.20. In terms of profitability, CBAY's ROE is -0.32%, compared to BLU's ROE of -0.06%. Regarding short-term risk, CBAY is less volatile compared to BLU. This indicates potentially lower risk in terms of short-term price fluctuations for CBAY.